CrossrefInfokarte
Compared with glyburide, sitagliptin associated with incremental cost-effectiveness ratio of $169 572 per QALY and exenatide with $278 935 per QALY as second-line treatment in adult diabetics in the USA
Evidence Based Medicine · 2010-04 · 15 (2) · 40-41
DOI: 10.1136/ebm1034 ↗Abstract
Kein Abstract verfügbar.
EUVIMED